
QUESTION: In patients with schizophrenia, is amisulpride effective and safe for treating symptoms?

Data sources
Studies were identified by searching Medline and Current Contents (to April 2000), scanning reference lists, and contacting the manufacturer of amisulpride.

Study selection
Studies were selected if they were randomised controlled trials that compared amisulpride with conventional antipsychotics and/or placebo in patients with schizophrenia.

Data extraction
Data were extracted on patients, drug regimens, study characteristics, and outcomes (including mean change from baseline on the Brief Psychiatric Rating Scale (BPRS) and for the Assessment of Negative Symptoms; extrapyramidal side effects (EPS) [number of patients needing ≥1 dose of antiparkinsonian medication]; and dropouts).

Main results
18 studies (2214 patients) met the selection criteria. Study duration ranged from 3 weeks to 1 year (mean 12 wks). Patients were mostly men in their 30s with moderate to severe schizophrenia (mean duration 3–37 y). Comparators were usually haloperidol and placebo; 4 studies compared amisulpride with flupentixol, perazine, and fluphenazine. Amisulpride led to a greater mean reduction in BPRS score from baseline than conventional antipsychotics in acutely ill patients (table). In patients with persistent, predominantly negative symptoms, amisulpride was better than placebo (but not conventional antipsychotics) for mean change in negative symptoms (table). In patients with acute exacerbations, amisulpride led to a greater mean change in negative symptoms relative to conventional antipsychotics (table). Amisulpride was better than conventional antipsychotics but was not different from placebo (which was compared with low dose amisulpride; 50–300 mg/d) for use of antiparkinsonian drugs (table). In acutely ill patients, fewer patients treated with amisulpride than with conventional drugs dropped out (table). In patients with predominantly persistent negative symptoms, fewer patients in the amisulpride group than in the placebo group dropped out; amisulpride and conventional antipsychotics did not differ for dropouts (table).

Conclusions
In patients with schizophrenia, amisulpride reduces symptoms and dropouts relative to placebo and reduces need for antiparkinsonian drugs relative to conventional antipsychotics. In acutely ill patients, amisulpride is more effective and leads to fewer dropouts than conventional antipsychotics.

Review: amisulpride is effective and safe for schizophrenia


Amisulpride (Am) v placebo or conventional antipsychotics (CAPs) for schizophrenia*

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Patient group</th>
<th>Comparison</th>
<th>Number of studies</th>
<th>Effect size r (95% CI)†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean change in BPRS score</td>
<td>Acutely ill</td>
<td>Am v CAPs</td>
<td>10</td>
<td>0.11 (0.06 to 0.16)</td>
</tr>
<tr>
<td>Mean change in negative symptoms</td>
<td>Persistent, predominantly negative symptoms</td>
<td>Am v placebo</td>
<td>4</td>
<td>0.26 (0.19 to 0.34)</td>
</tr>
<tr>
<td>Mean change in negative symptoms</td>
<td>Am v CAPs</td>
<td>3</td>
<td>0.08 (-0.12 to 0.26)</td>
<td></td>
</tr>
<tr>
<td>Mean change in negative symptoms</td>
<td>Acutely ill</td>
<td>Am v CAPs</td>
<td>5</td>
<td>0.14 (0.08 to 0.19)</td>
</tr>
<tr>
<td>≥1 dose of AP</td>
<td>Not specified</td>
<td>Am v placebo</td>
<td>4</td>
<td>0.01 (-0.08 to 0.22)‡</td>
</tr>
<tr>
<td>Drugs</td>
<td></td>
<td>Am v CAPs</td>
<td>12</td>
<td>0.25 (0.17 to 0.32)</td>
</tr>
<tr>
<td>Dropouts</td>
<td>Acutely ill</td>
<td>Am v CAPs</td>
<td>11</td>
<td>0.17 (0.08 to 0.26)</td>
</tr>
<tr>
<td></td>
<td>Persistent, predominantly negative symptoms</td>
<td>Am v placebo</td>
<td>NR</td>
<td>0.20 (0.12 to 0.28)‡</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Am v CAPs</td>
<td>3</td>
<td>0.08 (-0.08 to 0.23)‡</td>
</tr>
</tbody>
</table>

*AP=antiparkinsonian; NR=not reported. CI defined in glossary. †Positive values show benefit for amisulpride. §Not statistically significant.

COMMENTARY

Amisulpride warrants particular attention because its pharmacological profile is clearly distinct from other currently available atypicals. Other atypicals have greater serotonin 5-HT2, versus dopamine D5, antagonism, whereas amisulpride has no effects on the serotonin 5-HT4 system.

Amisulpride, like risperidone, has a risk of EPS that is dose-dependent and evident at high therapeutic doses. Another similarity to risperidone is the risk of elevated prolactin. Amisulpride’s superiority in acute psychosis for global and negative symptoms when compared with conventional antipsychotics must be qualified. These studies have routinely used conventional antipsychotic doses equivalent to ≥12 mg/day of haloperidol. Another meta-analysis showed that differences can be eliminated when comparisons with more appropriate doses are made. This caution in interpreting differences is relevant not only for negative symptoms but also for total scores. Again, this critique is not just levied at amisulpride but at all studies that compare newer antipsychotics with excessive doses of conventional agents.

Amisulpride’s superiority in patients with predominantly negative symptoms was seen in placebo controlled trials but not in the limited available comparisons with conventional antipsychotics. Insufficient data exist to indicate whether this is because of a unique superiority of amisulpride or the absence of data for other drugs in this group of patients.

In so far as amisulpride provides antipsychotic activity with low EPS, it, like others, is an atypical. As noted above, this conclusion is tempered by the high dose of comparison drugs. Any definitive statement regarding superior efficacy is made more difficult by the fact that the benefits are modest, and definitive trials in refractory patients have not been done (clozapine is the only drug with clear benefits in this segment). What is striking is that despite having a different pharmacology, the clinical profile is nearly indistinguishable from some of the newer atypicals. This not only makes amisulpride an interesting drug clinically, but may also elucidate much about the mechanism of what we now call atypicality.

Gary Remington, MD, PhD, FRCP (C)
Shitij Kapur, MD, PhD, FRCP (C)
University of Toronto, Toronto, Ontario, Canada